Want to see HK:0455 full AI Analyst Report?
Tianda Pharmaceuticals Ltd. (0455) Ratios
0 Followers
Tianda Pharmaceuticals Ltd. Ratios
HK:0455's free cash flow for Q4 2025 was HK$-14.19M. For the 2025 fiscal year, HK:0455's free cash flow was decreased by HK$-3.90M and operating cash flow was HK$-10.29M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Mar 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.83 | 0.86 | 1.10 | 1.54 | 2.13 |
| Quick Ratio | 0.64 | 0.70 | 0.89 | 1.41 | 1.85 |
| Cash Ratio | 0.27 | 0.34 | 0.52 | 0.94 | 1.23 |
| Solvency Ratio | -0.11 | -0.09 | 0.04 | -0.01 | 0.00 |
| Operating Cash Flow Ratio | 0.06 | -0.04 | -0.16 | 0.22 | -0.03 |
| Short-Term Operating Cash Flow Coverage | 0.18 | -0.08 | -0.52 | 1.22 | -0.14 |
| Net Current Asset Value | HK$ -93.80M | HK$ -43.48M | HK$ 18.86M | HK$ 123.95M | HK$ 202.37M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.18 | 0.17 | 0.12 | 0.13 | 0.14 |
| Debt-to-Equity Ratio | 0.29 | 0.25 | 0.19 | 0.22 | 0.21 |
| Debt-to-Capital Ratio | 0.23 | 0.20 | 0.16 | 0.18 | 0.17 |
| Long-Term Debt-to-Capital Ratio | 0.08 | 0.00 | 0.01 | 0.09 | 0.11 |
| Financial Leverage Ratio | 1.64 | 1.51 | 1.55 | 1.73 | 1.54 |
| Debt Service Coverage Ratio | -0.20 | -0.44 | 0.16 | -0.21 | 0.02 |
| Interest Coverage Ratio | 0.00 | -11.16 | -5.87 | -9.37 | -53.74 |
| Debt to Market Cap | 0.45 | 0.34 | 0.22 | 0.15 | 0.30 |
| Interest Debt Per Share | 0.06 | 0.06 | 0.06 | 0.07 | 0.07 |
| Net Debt to EBITDA | -4.40 | -0.84 | -3.12 | 10.01 | 33.74 |
| Profitability Margins | |||||
| Gross Profit Margin | 41.28% | 46.08% | 48.02% | 46.01% | 47.30% |
| EBIT Margin | -16.75% | -15.00% | -3.90% | -12.83% | -5.35% |
| EBITDA Margin | -4.78% | -15.00% | 2.94% | -3.64% | -1.01% |
| Operating Profit Margin | -16.75% | -16.41% | -5.45% | -12.83% | -7.64% |
| Pretax Profit Margin | -21.47% | -16.47% | -4.83% | -11.68% | -5.49% |
| Net Profit Margin | -21.67% | -18.60% | -4.54% | -9.99% | -4.25% |
| Continuous Operations Profit Margin | -21.75% | -18.61% | -4.70% | -10.79% | -4.25% |
| Net Income Per EBT | 100.96% | 112.94% | 94.01% | 85.56% | 77.36% |
| EBT Per EBIT | 128.17% | 100.35% | 88.53% | 91.03% | 71.89% |
| Return on Assets (ROA) | -9.36% | -8.02% | -2.63% | -5.02% | -1.86% |
| Return on Equity (ROE) | -15.33% | -12.13% | -4.08% | -8.70% | -2.86% |
| Return on Capital Employed (ROCE) | -10.62% | -10.53% | -4.81% | -9.66% | -4.37% |
| Return on Invested Capital (ROIC) | -9.07% | -8.45% | -4.00% | -8.14% | -3.16% |
| Return on Tangible Assets | -11.68% | -9.99% | -2.94% | -5.54% | -2.09% |
| Earnings Yield | -25.24% | -16.89% | -5.15% | -6.27% | -4.33% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.07 | 4.23 | 5.00 | 3.83 | 0.00 |
| Payables Turnover | 2.39 | 2.64 | 2.34 | 4.14 | 2.56 |
| Inventory Turnover | 4.24 | 4.42 | 4.25 | 6.12 | 3.59 |
| Fixed Asset Turnover | 0.80 | 0.85 | 1.29 | 1.36 | 1.12 |
| Asset Turnover | 0.43 | 0.43 | 0.58 | 0.50 | 0.44 |
| Working Capital Turnover Ratio | -8.52 | -156.15 | 4.70 | 2.18 | 1.46 |
| Cash Conversion Cycle | 23.02 | 30.52 | 3.23 | 66.73 | -41.13 |
| Days of Sales Outstanding | 89.65 | 86.38 | 72.97 | 95.35 | 0.00 |
| Days of Inventory Outstanding | 86.01 | 82.49 | 85.98 | 59.59 | 101.72 |
| Days of Payables Outstanding | 152.64 | 138.35 | 155.73 | 88.22 | 142.85 |
| Operating Cycle | 175.66 | 168.87 | 158.95 | 154.95 | 101.72 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.01 | -0.00 | -0.02 | 0.04 | -0.00 |
| Free Cash Flow Per Share | 0.00 | -0.02 | -0.05 | 0.03 | -0.03 |
| Dividend Paid and CapEx Coverage Ratio | 1.24 | -0.20 | -0.69 | 1.88 | -0.13 |
| Capital Expenditure Coverage Ratio | 1.24 | -0.23 | -0.75 | 3.24 | -0.15 |
| Operating Cash Flow Coverage Ratio | 0.11 | -0.08 | -0.44 | 0.56 | -0.05 |
| Operating Cash Flow to Sales Ratio | 0.04 | -0.03 | -0.09 | 0.14 | -0.02 |
| Free Cash Flow Yield | 1.01% | -14.39% | -24.76% | 6.29% | -12.37% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.96 | -5.92 | -19.40 | -15.94 | -23.11 |
| Price-to-Sales (P/S) Ratio | 0.86 | 1.10 | 0.88 | 1.59 | 0.98 |
| Price-to-Book (P/B) Ratio | 0.61 | 0.72 | 0.79 | 1.39 | 0.66 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 99.20 | -6.95 | -4.04 | 15.91 | -8.08 |
| Price-to-Operating Cash Flow Ratio | 19.23 | -37.47 | -9.42 | 11.01 | -60.90 |
| Price-to-Earnings Growth (PEG) Ratio | -0.28 | -0.04 | 0.35 | -0.11 | 1.40 |
| Enterprise Value Multiple | -22.37 | -8.19 | 26.81 | -33.75 | -63.65 |
| Enterprise Value | 345.21M | 405.11M | 419.86M | 671.54M | 327.39M |
| EV to EBITDA | -22.37 | -8.19 | 26.81 | -33.75 | -63.65 |
| EV to Sales | 1.07 | 1.23 | 0.79 | 1.23 | 0.64 |
| EV to Free Cash Flow | 123.46 | -7.75 | -3.62 | 12.27 | -5.28 |
| EV to Operating Cash Flow | 23.94 | -41.77 | -8.44 | 8.49 | -39.80 |
| Tangible Book Value Per Share | 0.14 | 0.16 | 0.23 | 0.26 | 0.31 |
| Shareholders’ Equity Per Share | 0.21 | 0.24 | 0.28 | 0.29 | 0.35 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.01 | -0.13 | 0.03 | 0.08 | 0.23 |
| Revenue Per Share | 0.15 | 0.15 | 0.25 | 0.25 | 0.24 |
| Net Income Per Share | -0.03 | -0.03 | -0.01 | -0.03 | -0.01 |
| Tax Burden | 1.01 | 1.13 | 0.94 | 0.86 | 0.77 |
| Interest Burden | 1.28 | 1.10 | 1.24 | 0.91 | 1.03 |
| Research & Development to Revenue | 0.03 | 0.04 | 0.02 | 0.07 | 0.03 |
| SG&A to Revenue | 0.55 | 0.58 | 0.16 | 0.15 | 0.14 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | -0.21 | 0.18 | 2.06 | -1.45 | 0.29 |
Currency in HKD
